Literature DB >> 25905597

Long-term Risk of Melanoma-Related Mortality for Patients With Uveal Melanoma Treated With Proton Beam Therapy.

Anne Marie Lane1, Ivana K Kim1, Evangelos S Gragoudas1.   

Abstract

IMPORTANCE: Little is known about the long-term risk of dying of uveal melanoma after treatment with radiotherapy.
OBJECTIVE: To determine the long-term risk of dying of this disease, we evaluated melanoma-related mortality rates up to 25 years after proton beam therapy in a large series of patients with uveal melanoma. DESIGN, SETTING, AND PARTICIPANTS: In this analysis, we included 3088 patients with uveal melanoma, identified from a hospital-based cohort and treated with proton irradiation between January 1975 and December 2005. Vital status and cause of death were ascertained through active follow-up and searches of government databases (the Social Security Death Index and the National Death Index) through December 31, 2008. Cumulative rates of melanoma-related mortality were calculated using the Kaplan-Meier method. Patient and tumor characteristics of known prognostic significance for melanoma-associated death were evaluated, including patient age and tumor dimensions. MAIN OUTCOMES AND MEASURES: The primary outcome measure was cumulative rates of melanoma-specific mortality, and secondary measures included annual melanoma-specific mortality hazard rates and cumulative all-cause mortality rates.
RESULTS: Of 1490 deceased patients, 620 (41.6%) died of ocular melanoma. In addition, 19 patients were alive, but their melanoma metastasized, by the end of the observation period (mean follow-up after diagnosis of metastasis, 5.3 years). All-cause mortality rates in this cohort were 49.0% (95% CI, 47.0-51.1) at 15 years, 58.6% (95% CI, 56.4%-60.8%) at 20 years, and 66.8% (95% CI, 64.2%-69.4%) at 25 years. Melanoma-related mortality rates were 24.6% (95% CI, 22.8-26.4) at 15 years after treatment, 25.8% (95% CI, 24.0-27.8) at 20 years after treatment, and 26.4% (95% CI, 24.5-28.5) at 25 years after treatment. The 20-year mortality rate was 8.6% (95% CI, 6.2-11.9) for younger patients (≤ 60 years) with small tumors (≤ 11 mm) and 40.1% (95% CI, 36.1-44.3) for older patients (>60 years) with large tumors (>11 mm). CONCLUSIONS AND RELEVANCE: In this large series of patients with ocular melanoma treated conservatively with proton beam irradiation, the cumulative melanoma-related mortality rates continued to increase up to 23 years after treatment. Annual rates decreased considerably (to <1%) 14 years after treatment. Information regarding the long-term risk of dying of uveal melanoma may be useful to clinicians when counseling patients.

Entities:  

Mesh:

Year:  2015        PMID: 25905597     DOI: 10.1001/jamaophthalmol.2015.0887

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  10 in total

1.  SIRT2 Expression Is Higher in Uveal Melanoma than In Ocular Melanocytes.

Authors:  Danielle G Halfed; Pablo Zoroquiain; Henry A Wood; Paula Blanco; Nouf Al-Saati; Sultan Aldrees; Vasco Bravo-Filho; Miguel N Burnier
Journal:  Ocul Oncol Pathol       Date:  2015-10-17

2.  Postradiation Optic Atrophy Is Associated With Intraocular Pressure and May Manifest With Neuroretinal Rim Thinning.

Authors:  Lauren A Dalvin; Christopher L Deufel; Kimberly S Corbin; Ivy A Petersen; Timothy W Olsen; Gavin W Roddy
Journal:  J Neuroophthalmol       Date:  2021-11-11       Impact factor: 4.415

3.  Long-term relative survival in uveal melanoma: a systematic review and meta-analysis.

Authors:  Gustav Stålhammar; Christina Herrspiegel
Journal:  Commun Med (Lond)       Date:  2022-03-01

4.  Uveal melanoma: Long-term survival.

Authors:  Tomas Radivoyevitch; Emily C Zabor; Arun D Singh
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

Review 5.  Proton beam therapy for cancer in the era of precision medicine.

Authors:  Man Hu; Liyang Jiang; Xiangli Cui; Jianguang Zhang; Jinming Yu
Journal:  J Hematol Oncol       Date:  2018-12-12       Impact factor: 17.388

Review 6.  New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Authors:  Krzysztof Bilmin; Kamil J Synoradzki; Anna M Czarnecka; Mateusz J Spałek; Tamara Kujawska; Małgorzata Solnik; Piotr Merks; Mario Damiano Toro; Robert Rejdak; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

7.  Treatment of Uveal Melanoma With Radioactive Iodine 125 Implant Compared With Proton Beam Radiotherapy.

Authors:  James P Bolling; Roi Dagan; Michael Rutenberg; Maria Mamalui-Hunter; Steven J Buskirk; Michael G Heckman; Alexander P Hochwald; Roelf Slopsema
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2021-12-22

8.  Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Authors:  Pedro Grachinski Buiar; Sérgio Jobim de Azevedo
Journal:  Front Oncol       Date:  2017-05-18       Impact factor: 6.244

9.  Proton beam irradiation inhibits the migration of melanoma cells.

Authors:  Katarzyna Jasińska-Konior; Katarzyna Pochylczuk; Elżbieta Czajka; Marta Michalik; Bożena Romanowska-Dixon; Jan Swakoń; Krystyna Urbańska; Martyna Elas
Journal:  PLoS One       Date:  2017-10-10       Impact factor: 3.240

10.  Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours.

Authors:  Peter A Johansson; Kelly Brooks; Felicity Newell; Jane M Palmer; James S Wilmott; Antonia L Pritchard; Natasa Broit; Scott Wood; Matteo S Carlino; Conrad Leonard; Lambros T Koufariotis; Vaishnavi Nathan; Aaron B Beasley; Madeleine Howlie; Rebecca Dawson; Helen Rizos; Chris W Schmidt; Georgina V Long; Hayley Hamilton; Jens F Kiilgaard; Timothy Isaacs; Elin S Gray; Olivia J Rolfe; John J Park; Andrew Stark; Graham J Mann; Richard A Scolyer; John V Pearson; Nicolas van Baren; Nicola Waddell; Karin W Wadt; Lindsay A McGrath; Sunil K Warrier; William Glasson; Nicholas K Hayward
Journal:  Nat Commun       Date:  2020-05-15       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.